ACS Medicinal Chemistry Letters
Page 6 of 7
(
1) Tessarz, P.; Kouzarides, T. Histone core modifications regulating
nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 2014,
5, 703ꢀ708.
2) Haberland, M.; Montgomery, R.L.; Olson E.N.; The many roles of
Yan, F.; Yu, D.; Zawadke, L.; Zhu, X.; Zhu, X.; Sims, R.J.; Cochran,
A.G.; Bellon, S.; Audia, J.E.; Magnuson, S.; Albrecht, B.K. Fragꢀ
mentꢀbased discovery of a selective and cellꢀactive benzodiazepinone
CBP/EP300 bromodomain inhibitor (CPIꢀ637). ACS Med. Chem. Lett.
2016, 7, 531ꢀ536.
17. Conery, A.R.; Centore, R.C.; Neiss, A.; P. J. Keller, P. J. ;
Joshi, S.; Spillane, K. L.; Sandy, P.; Hatton, C.; Pardo, E.; Zawadzke,
L.; Bommiꢀ Reddy, A.; Gascoigne, K.E.; Bryant, B.M.; Mertz,
J.A.; Sims III, R.J. Bromodomain inhibition of the transcriptional
coactivators CBP/EP300 as a therapeutic strategy to target the IRF4
network in multiple myeloma. eLIFE published online January 5,
2016. DOI: 10.7554/eLife.10483
18. Bowers E.M.; Yan, G.; Mukherjee, C.; Orry, A.; Wang, L.; Holꢀ
bert, M.A.; Crump, N.T.; Hazzalin, C.A.; Liszczak, G.; Yuan, H.;
Larocca, C.; Saldanha, S.A.; Abagyan, R.; Sun, Y.; Meyers, D.J.;
Marmorstein, R.; Mahadevan, L.C.; Alani, R.M.; Cole, P.A. Virtual
ligand screening of the p300/CBP histone acetyltransferase: identifiꢀ
cation of a selective small molecule inhibitor. Chem. Biol. 2010, 17,
471ꢀ482.
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
1
(
histone deacetylases in development and physiology: implications for
disease and therapy. Nat. Rev. Genet. 2009, 10, 32ꢀ42.
(3) Yuan, H.; Marmostein, R. Histone acetyltransferases: Rising anꢀ
cient counterparts to protein kinases. Biopolymers 2013, 99, 98ꢀ 111.
(
4) Simon, R.P.; Robaa, D.; Alhalabi, Z.; Sippl, W.; Jung, M. KATchꢀ
ingꢀup on small molecule modulators of lysine acetyltransferases. J.
Med. Chem. 2016, 59, 1249ꢀ1270.
(5) Richters, A.; Koehler, A.N. Epigenetic modulation using small
moleculesꢀtargeting histone acetyl transferases in Disease. Curr. Med.
Chem. 2017, 24, 1ꢀ30.
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
(
6) Attar, N.; Kurdistani, S.K. Exploitation of EP300 and CREBB
lysine acetyltransferase by cancer. Cold Spring Harb. Perspect. Med.
2017;7:a026534.
(
7) Wang, L.; Tang, Y.; Cole, P.A.; Marmorstein, R. Structure and
function of the p300/CBP and Rtt109 histone acetyl transferases:
implications for histone acetyltransferase evolution and function.
Curr. Opin. Struct. Biol. 2008, 18, 741ꢀ747.
8. Jin, Q.; Yu, LꢀR.; Wang, L.; Zhang, Z.; Kasper, L.H.; Lee, JꢀE.;
Wang, C.; Brindle, P.K.: Dent, S. Y.R.; Ge, K. Distinct roles of
GCN5/PCAF PCAFꢀmediated H3K9ac and CBP/p300ꢀmediated
H3K18/27ac in nuclear receptor transactivation. EMBO J. 2011, 30,
19. Shrimp, J.H.; Sorum, A.W.; Garlick, J.M.; Guasch, L.; Nicklaus,
M.C. ; Meier, J.L. Characterizing the covalent targets of a small molꢀ
ecule inhibitor of the lysine acetyltransferase P300. ACS Med. Chem.
Lett. 2016, 7, 151ꢀ155.
20. Van den Bosch, T.; Boichencko, A.; Leus, N.G.J.; Ourailidou,
M.E.; Wapenaar, H.; Rotili, D.; Mai, A.; Imhof, A.; Bischoff, R.;
Haisam, H.J.; Dekker, F.J. The histone acetyltransferase p300 inhibiꢀ
tor C646 reduces proꢀinflammatory gene expression and inhibits hisꢀ
tone deacetylases. Biochem. Pharmacol. 2016, 102, 130ꢀ140.
21. Blagg, J.; Workman, P. Choose and use your chemical probe
wisely to explore cancer biology. Cancer Cell 2017, 32, 9ꢀ25.
22. Lasko, L.M.; Jakob, C.S.; Edajli, R.P.; Qiu, W.; Montgomery, D.;
Digiammarino, E.L; Hansen, T.M.; Risi, R.M.; Frey, R.; Manaves V.;
Bailin, S.; Algire, M.; Hessler, P.; Lam, L.T.; Uziel, T.; Faivre, E.;
Ferguson, D.; Buchanan, F.G.; Martin, R.L.; Torrent, M.; Chiang, G.
G.; Karakurichi, K.; Langston, J.W.; Weinert, B.T.; Choudhary, C.;
DeVries, P.; Van Drie, J.H.; McElligott, D.; Kesicki, E.; Marmorstein,
R.; Sun, C.; Cole, P.A.; Rosenberg, S.; Michaelides, M.R.; Lai, A.;
Brombers, K.D. Discovery of a selective catalytic p300/CBP inhibiꢀ
tor that targets lineageꢀspecific tumours. Nature 2017, 550, 128ꢀ132.
23. Liu, X.; Wang, W.; Zhao, K.; Thompson, P.R.; Hwang, Y.; Marꢀ
morstein, R.; Cole, P.A. The structural basis of protein acetylation by
the p300/CBP transcriptional coactivator. Nature 2008, 451, 846ꢀ850.
24. Marques, O.; Sanejouand, Y.H. Hingeꢀbending motion in citrate
synthase arising from normal mode calculations. Proteins 1995, 23,
557ꢀ560.
25. Wiegand, G.; Remington, S.J. Citrate Synthase: structure, control,
and mechanism. Annu. Rev. Biophys. Biophys. Chem. 1986, 15, 97ꢀ
117.
26. Hickman, A.B.; Namboodiri, M.A.; Klein, D.C.; Dyda, F. The
structural basis of ordered substrate binding by serotonin Nꢀ
acetyltransferase enzyme complex at 1.8 Å resolution with a bisubꢀ
strate analog. Cell 1999, 97, 361–369.
27. LE = ꢀ1.4 logKi/# heavy atoms; LipE = ꢀlogKiꢀclogP.
28. Zhang, Y.; Lao, L.; Lin, J.; Gao, H.; Wilson, T.C.; Giragossian, C.
Lack of appreciable species differences in nonspecific microsomal
binding. J. Pharm. Sci. 2010, 99, 3620ꢀ3627.
29. Liu, X.; Wright, M.; Hop, C.E. Rational use of plasma binding
and tissue binding data in drug design. J.Med.Chem. 2014, 57, 8238ꢀ
48.
2
49ꢀ262.
9. Farria, A.; Li, W.; Dent, S. KATs in Cancer: functions and theraꢀ
pies. Oncogene 2015, 34, 4901ꢀ4913.
1
0. Valor, L.M.; Viosca J.; LopezꢀAtalaya J.P.; Barco A. Lysine
acetyltransferases CBP and p300 as therapeutic targets in cognitive
and neurodegenerative disorders. Curr. Pharm. Design 2013, 19,
5
061ꢀ64.
11. Gang, E.J.; Hsieh, Y.T.; Pham, J.; Zhao, Y.; Nguyen, C.;
Huantes, S.; Park, E.; Naing, K.; Klemm, L.; Swaminathan, S.; Conꢀ
way, E.M.; Pelus, L.M.; Crispino, J.; Mullighan, C.G.; McMillan,
M.; Müschen, M.; Kahn, M.; Kim, Y.M. Smallꢀmolecule inhibition
of CBP/catenin interactions eliminates drugꢀresistant clones in acute
lymphoblastic leukemia. Oncogene 2014, 33, 2169ꢀ2178.
1
2. Lao, B.B.; Grishagin, I.; Mesallati, H.; Brewer, T.F.; Olenyuk,
B.Z.; Arora, P.S. In vivo modulation of hypoxiaꢀinducible signaling
by topographical helix mimetics. Proc. Nat. Acad. Sci. U. S. A. 2014
1
11, 7531ꢀ6.
13. Hay, D.A.; Fedorov, O.; Martin, S.; Singleton, D.C.; Tallant, C.;
Wells, C.; Picaud, S.; Philpott, M.; Monteiro, O.P.; Rogers, C.M.;
Conway, S.J.; Rooney, T.P.C.; Tumber, A.; Yapp, C.; Filippakopouꢀ
los, P.; Bunnage, M.A. Muller, S. ;Knapp, S.; Schofield, C.J.; Brenꢀ
nan, P.E. Discovery and optimization of smallꢀmolecule ligands for
the CBP/p300 bromodomains. J.Am.Chem.Soc. 2014, 136, 9308ꢀ
9319.
1
4. Dancy, B.M.; Cole, P.A. Protein lysine acetylation by p300/CBP.
Chem. Rev. 2015, 115, 2419ꢀ2452.
5. Picaud, S.; Fedorov, O.; Thanasopoulou, A.; Leonards, K.; Jones,
1
K.; Meier, J.;, Olzscha, H.; Monteiro, O.; Martin, S.; Philpott M.;
Tumber, A.; Filippakopoulos. P.; Yapp, C.; Wells, C.; Che, K.H.;
Bannister, A.; Robson, S.; Kumar, U.; Parr, N.; Lee, K.; Lugo, D.;
Jeffrey, P.; Taylor, S.; Vecellio, M.L.; Bountra, C.; Brennan, P.E.;
O'Mahony, A.; Velichko, S.; Muller, S.; Hay, D.; Daniels D.L.; Urh,
M.; La Thangue, N.B.; Kouzarides, T.; Prinjha, R.; Schwaller, J.;
Knapp, S. Generation of a selective small molecule inhibitor of the
CBP/p300 bromodomain for leukemia therapy. Cancer Res. 2015, 75,
30. Fa*Fg = fraction absorbed* fraction escaping gut metabolism = F
/(1ꢀCLp/Liver blood flow).
5
1
106ꢀ5119.
6. Taylor, M.A.; Cote, A.; Hewitt, M.C.; Pastor, R.; Leblanc, Y.;
Nasveschik, C.G.; Romero, F.A.; Crawford, T.D.; Cantone, N.; Jaꢀ
rayami, H.; Setser, J.; Murray, J.; Beresini, M.H.; Boenig, G.L.; Chen,
Z.; Conery, A.R.; Cummings, R.T.; Dakin, L.A.; Flynn, E.M.; Huang,
O.W.; Kaufman, S.; Keller, P.J.; Kiefer, J.R.; Lai, T.; Li, Y.; Liao, J.;
Liu, W.; Lu, H.; Pardol, E.; Tsui, V.; Wang, J.; Wang, Y.; Xu, Z.;
6
ACS Paragon Plus Environment